Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Double-blind, crossover, placebo-controlled trial of bromocriptine in patients with sleep bruxism
Autore:
Lavigne, GJ; Soucy, JP; Lobbezoo, F; Manzini, C; Blanchet, PJ; Montplaisir, JY;
Indirizzi:
Hop Sacre Coeur, Ctr Etud Sommeil, Montreal, PQ H4J 1C5, Canada Hop Sacre Coeur Montreal PQ Canada H4J 1C5 , Montreal, PQ H4J 1C5, Canada CHU Montreal, Dept Nucl Med, Montreal, PQ, Canada CHU Montreal Montreal PQ Canada eal, Dept Nucl Med, Montreal, PQ, Canada CHU Montreal, Dept Stomatol, Montreal, PQ, Canada CHU Montreal Montreal PQ Canada eal, Dept Stomatol, Montreal, PQ, Canada CHU Montreal, Dept Neurol, Montreal, PQ, Canada CHU Montreal Montreal PQ Canada treal, Dept Neurol, Montreal, PQ, Canada Acad Ctr Dent Amsterdam, Dept Oral Funct, NL-1066 EA Amsterdam, Netherlands Acad Ctr Dent Amsterdam Amsterdam Netherlands NL-1066 EA am, Netherlands
Titolo Testata:
CLINICAL NEUROPHARMACOLOGY
fascicolo: 3, volume: 24, anno: 2001,
pagine: 145 - 149
SICI:
0362-5664(200105/06)24:3<145:DCPTOB>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
RESTLESS LEGS SYNDROME; DRUG EXPOSURE; PROPRANOLOL; SECONDARY; ECSTASY;
Keywords:
sleep; sleep bruxism; dopamine; periodic movement; iodine-123-iodobenzamide (IBZM); single photon emission computed tomography; controlled clinical trial;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Lavigne, GJ Univ Montreal, Fac Med Dent, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada Univ Montreal CP 6128,Succursale Ctr Ville Montreal PQ Canada H3C 3J7
Citazione:
G.J. Lavigne et al., "Double-blind, crossover, placebo-controlled trial of bromocriptine in patients with sleep bruxism", CLIN NEUROP, 24(3), 2001, pp. 145-149

Abstract

This study was designed to assess the effects of bromocriptine, a dopamineD2 receptor agonist, on sleep bruxism. Seven otherwise healthy patients with severe and frequent sleep bruxism participated in this randomized. double-blind, placebo-controlled study. The study used a crossover design that included 2 weeks of active treatment or placebo with a washout period of 1 week. To further evaluate whether bromocriptine influences striatal D2 receptor binding, we used iodine-123-iodobenzamide single photon emission computed tomography (SPECT) under both placebo and bromocriptine regimens. Bromocriptine did not reduce the frequency of episodes of bruxism during sleep (mean +/- SEM, 9.0 +/- 1.0 and 9.6 +/- 1.5 bruxism episodes per hour for placebo and bromocriptine, respectively) or the amplitude of masseter muscle contractions (root mean square values. 48.2 +/- 15.5 muV and 46.9 +/- 12.7 muV for placebo and bromocriptine, respectively). SPECT also failed to revealthat either treatment had any influence on striatal D2 binding (values fortotal binding in counts:pixel, 1.80 [1.72-1.93] and 1.79 [1.56-1.87] for placebo and bromocriptine, respectively). This study shows that a nightly dose of bromocriptine does not exacerbate or reduce sleep bruxism motor activity.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/20 alle ore 12:49:19